Non-Hodgkin Lymphoma Market - 2024-2031

February 2024 | 46 pages | ID: NCEB009AE52FEN
DataM Intelligence

Abstracts

Non-Hodgkin Lymphoma Marketis is growing with a CAGR of 8.20% during the forecast period 2026-2035.

The Non-Hodgkin Lymphoma Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Non-Hodgkin Lymphoma Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Disease Type

• B-cell Lymphomas*
• T-cell Lymphoma

By Drug Class

• Monoclonal Antibodies*
• Antibody-Drug Conjugates
• BTK/BCL-2 Kinase Inhibitors
• PI3 Kinase Inhibitors
• Protease Inhibitors
• PD1 Inhibitors
• Immunomodulatory Drugs
• Chemotherapy Agents
• CAR T-Cell Therapy

By Route of Administration

• Oral*
• Parenteral
• Others

By Distribution Channel

• Hospital Pharmacies*
• Retail Pharmacies
• Online Pharmacies

Regional Analysis for Non-Hodgkin Lymphoma Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Non-Hodgkin Lymphoma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Disease Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. The Growing Regulatory Approvals for Non-Hodgkin Lymphoma
    4.1.1.2. The Increasing Clinical Trials for Non-Hodgkin Lymphoma Drugs
  4.1.2. Restraints
    4.1.2.1. Lack of Specific Targeted Therapies for Treating Non-Hodgkin Lymphoma
  4.1.3. Opportunity
    4.1.3.1. Exploring Combination Therapies for Enhanced Non-Hodgkin Lymphoma Treatment
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

6.1. Analysis of COVID-19
  6.1.1. Scenario Before COVID-19
  6.1.2. Scenario During COVID-19
  6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion

7. RUSSIA-UKRAINE WAR ANALYSIS

8. BY DISEASE TYPE

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  8.1.2. Market Attractiveness Index, By Disease Type
8.2. B-cell Lymphomas*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. T-cell Lymphoma

9. BY DRUG CLASS

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  9.1.2. Market Attractiveness Index, By Drug Class
9.2. Monoclonal Antibodies*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Antibody-Drug Conjugates
9.4. BTK/BCL-2 Kinase Inhibitors
9.5. PI3 Kinase Inhibitors
9.6. Protease Inhibitors
9.7. PD1 Inhibitors
9.8. Immunomodulatory Drugs
9.9. Chemotherapy Agents
9.10. CAR T-Cell Therapy

10. BY ROUTE OF ADMINISTRATION

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.1.2. Market Attractiveness Index, By Route of Administration
10.2. Oral*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Parenteral
10.4. Others

11. BY DISTRIBUTION CHANNEL

11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2. Market Attractiveness Index, By Distribution Channel
11.1. Hospital Pharmacies*
  11.1.1. Introduction
  11.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.2. Retail Pharmacies
11.3. Online Pharmacies

12. BY REGION

12.1. Introduction
  12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  12.1.2. Market Attractiveness Index, By Region
12.2. North America
  12.2.1. Introduction
  12.2.2. Key Region-Specific Dynamics
  12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    12.2.7.1. The U.S.
    12.2.7.2. Canada
    12.2.7.3. Mexico
12.3. Europe
  12.3.1. Introduction
  12.3.2. Key Region-Specific Dynamics
  12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    12.3.7.1. Germany
    12.3.7.2. The U.K.
    12.3.7.3. France
    12.3.7.4. Italy
    12.3.7.5. Spain
    12.3.7.6. Rest of Europe
12.4. South America
  12.4.1. Introduction
  12.4.2. Key Region-Specific Dynamics
  12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    12.4.7.1. Brazil
    12.4.7.2. Argentina
    12.4.7.3. Rest of South America
12.5. Asia Pacific
  12.5.1. Introduction
  12.5.2. Key Region-Specific Dynamics
  12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    12.5.7.1. China
    12.5.7.2. India
    12.5.7.3. Japan
    12.5.7.4. Australia
    12.5.7.5. Rest of Asia Pacific
12.6. Middle East and Africa
  12.6.1. Introduction
  12.6.2. Key Region-Specific Dynamics
  12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. COMPETITIVE LANDSCAPE

13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies

14. COMPANY PROFILES

14.1. AbbVie, Inc. (Pharmacyclics LLC) *
  14.1.1. Company Overview
  14.1.2. Product Portfolio and Description
  14.1.3. Financial Overview
  14.1.4. Key Developments
14.2. AstraZeneca plc
14.3. Bayer AG
14.4. Bristol-Myers Squibb Company (Celgene Corp.)
14.5. Gilead Sciences, Inc. (Kite Pharma)
14.6. Johnson & Johnson (Janssen Biotech, Inc.)
14.7. Merck & Co., Inc.
14.8. Novartis AG
14.9. Roche Holding AG (F. Hoffmann-La Roche AG)
14.10. Seagen, Inc. (Seattle Genetics, Inc.)
14.11. Takeda Pharmaceutical Co., Ltd.
14.12. Teva Pharmaceutical Industries Ltd.(*LIST NOT EXHAUSTIVE)

15. APPENDIX

15.1. About Us and Services
15.2. Contact Us